Dr Amit Oza is a medical oncologist at Princess Margaret Cancer Centre (PM), Scientist at the Ontario Cancer Institute, and Professor of Medicine at the University of Toronto. Dr Oza is Head of Division of Medical Oncology & Haematology and Director of Clinical Research at PM, as well as co-Director of the Robert & Maggie Bras and Family New Drug Development Program. He serves as Chair of the NCI Investigational Drug Steering Committee (from June 2014) and co-chair (from June 2016) of NCI Gynaecologic Cancer Steering Committee. He is on the Executive Board of the international Gynaecologic Cancer InterGroup and Chair Elect (commencing June 2019). As well as co-founder and Director of the Fields Institute Centre for Mathematical Modelling.
Dr Oza’s academic interest is the design and development of early phase clinical trials for targeted agents with a defined research interest in gynaecologic malignancies and focus on translational science. Since 2006, he has been Principal Investigator of the Phase II Consortium N01-cnotract (2006-16) sponsored by the National Cancer Institute. This program has developed, designed and led over 100 early phase clinical trials since its inception in 2001 and enrolled over 3500 patients from across Canada and US. Under Amit’s direction, Princess Margaret is home to one of the largest early phase ovarian cancer clinical trials programs enrolling 150 patients/year onto clinical trials at the Institute. A highly productive program, he has been responsible for $17.4M in new funding over the last five years from peer-reviewed agencies such as the U.S NCI, Department of Defence, Cancer Care Ontario, Ontario Institute for Cancer Research and Princess Margaret Cancer Foundation.